Table 4.
Post transplant complications in BL-ASCT group.
| Age gender | Diagnosis | Conditioning regimen | Days in ICU | Bleeding WHO grade | PL Nadir × 109/L | Hgb Nadir g/dL | Comments |
|---|---|---|---|---|---|---|---|
| 5 F | MM | Mel200 | 0 | ≤2 | 38 | 12.8 | Mild hematemesis |
| 62 F | NHL | R-BEAM | 0 | ≤2 | 2 | 8.3 | Hematemesis |
| 57 F | MM | Mel100 | 13 | 3 | 1 | 5.4 | Cardiac tamponade, rectal bleeding, H1N1 influenza, ARDS, sepsis, and multiorgan failure |
| 30 F | CNS GCT | Carbo/Thio/VP16 | 3 | 4 | 31 | 14 | CNS bleed, died despite maximum supportive care |
| 21 M | HL | BEAM | 0 | 3 | 1 | 6.6 | Lower GI bleeding |
| 37 F | HL | BEAM | 0 | 3 | 5 | 6.4 | Vaginal bleeding, epistaxis, blood in sputum |
| 64 M | NHL | R-BEAM | 0 | ≤2 | 3 | 7.1 | Hematuria |
| 24 F | HL | BEAM | 0 | ≤2 | 2 | 8.9 | Vaginal spotting |
| 17 F | NHL | BEAM | 0 | ≤2 | 5 | 7.3 | Gum bleeding |
| 47 M | NHL | BEAM | 0 | ≤2 | 2 | 7.2 | Petechiae lower extremities |
| 53 F | MM | Mel200 | 0 | ≤2 | 2 | 7.7 | Mild epistaxis |
| 52 F | MM | Mel200 | 0 | ≤2 | 9 | 8.6 | Epistaxis |
| 67 F | MM | Mel200 | 1 | 2 | 8.3 | A fib | |
| 61 M | MM | Mel200 | 2 | 8 | 7.5 | A fib w/RVR | |
| 66 F | NHL | R-BEAM | 0 | 2 | 8.1 | A fib w/RVR | |
| 60 M | NHL | BEAM | 0 | 3 | 7.7 | A fib | |
| 53 M | MM | Mel200 | 0 | 13 | 11.6 | SVT, adenosine administered | |
| 57 M | MM | Mel200 | 4 | 5 | 9 | SVT, HTN | |
| 61 F | ALL | TBI/Cy | 0 | 4 | 10.4 | Tonic–clonic seizure |
MM multiple myeloma, NHL non-Hodgkin’s lymphoma, HL Hodgkin’s lymphoma, CNS GCT central nervous system germ cell tumor, ALL acute lymphoblastic lymphoma, Mel melphalan, Carbo carboplatin, Thio thiotepa, VP16 etoposide, R rituximab, ARDS acute respiratory distress syndrome, GI gastrointestinal, A fib atrial fibrillation, RVR rapid ventricular response, SVT supraventricular tachycardia, HTN hypertension